Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
Thursday, March 06, 2014 9:58:43 AM
We will have to wait and see. If the company does not issue a statment by Monday, that might be a positive for such a buyout potential. The writer of the latest Seeking Alpha post that indicates the acquisition talks are underway could get in a lot of trouble if false and he recently covered shorts or bought in.
Strange days for NNVC stock. At 3.375 billion and 54 million, lets say 60 million shares, I think $56.25/share would be nice, but far under its true value!
From the Seeking Alpha Post/Article:
NanoViricides (NNVC) Acquisition In Review 0 comments
Mar 5, 2014 5:23 PM | about stocks: NNVC
A source close to the matter has stated that NanoViricides (NNVC) is in the process of being acquired. "Due to recent developments in the company, we are intent on acquiring it for defensive purposes along with expansion of our drug line-up, among other development based factors. We have valued it between 2.25 and 4.5 billion dollars, although we are yet to reach an agreement."
The source has said that the full details will "hopefully be agreed upon and fully disclosed by the end of this month", and that this acquisition will entail all aspects of the company, its stock, and licenses. The financial promise that this acquisition brings along is uncertain although this valuation is multiple times larger than NanoViricides market cap, but we must keep in mind its market cap may not reflect the value of its licenses and technologies, and whatever this "recent developments" means for the companies valuation. This source has disclosed that they are "unwilling to disclose any further information" due to their key role in the acquisition which may reveal their identity in a still unsigned deal.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM